SciSparc: NeuroThera Labs Granted U.S. Patent for Cannabinoid Technology to Overcome Antimicrobial Resistance such as MRSA

NeuroThera’s Proprietary Cannabinoid-Enhanced Platform Targets Antibiotic Resistance Using Approved Antimicrobials TEL AVIV, ...

SciSparc Subsidiary NeuroThera Wins U.S. Patent for Cannabinoid-Based Antimicrobial Resistance Platform

On February 2, 2026, SciSparc Ltd. reported that its approximately 75%-owned subsidiary NeuroThera Labs Inc. has been granted a new U.S. patent covering proprietary combinations of established ...
Rolling Out

7 facts about MRSA that threatens public health

The story of MRSA begins just four years after methicillin entered medical practice in 1959. The bacteria had already developed resistance to the new antibiotic, demonstrating the remarkable ...

Metal-based compounds may be the future of antibiotics

Scientists are putting the pedal to the metal to develop new antibiotics. Metal-based drugs can open a new world of medicine, ...
Healthline

MSSA vs. MRSA: Understanding the Difference

MSSA and MRSA are Staphylococcus aureus (S. aureus) bacteria with different resistance patterns. MRSA is resistant to many antibiotics and is more difficult to treat. Both types of bacteria can cause ...